Imikeraderm, (Imiquimod)

Imiquimod activates Toll‑like receptor 7 on immune cells in the skin, leading to the production of cytokines such as interferon‑α and interleukin‑12. These signaling molecules boost both innate and adaptive immunity, producing antiviral effects and promoting the destruction of dysplastic or neoplastic cells.

The dosing regimen for Imikeraderm is determined by the prescribing clinician based on the specific indication, lesion size, and patient factors. The prescriber will provide detailed instructions on the amount of cream to apply, frequency, and duration of treatment.

Safety of Imikeraderm in pregnancy has not been established, and it is generally avoided unless the potential benefit outweighs the risk. Likewise, use while breastfeeding is not recommended because the effects on the infant are unknown. Consultation with a healthcare professional is essential.

To place an order, submit an enquiry on the Imikeraderm product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other topical agents such as podophyllotoxin or sinecatechins, Imikeraderm uses an immune‑mediated mechanism rather than direct antiviral activity. This can result in higher clearance rates for some patients, but it may also cause more local skin irritation. Choice of therapy depends on lesion characteristics and patient tolerance.

Imikeraderm should be stored at room temperature, below 25 °C, in its original tube. Keep the product away from moisture, direct sunlight, and extreme temperatures to maintain stability and potency.

The cream is applied topically to the affected skin area using a fingertip or applicator as directed by the prescriber. The medication is usually spread in a thin layer, left on the skin for the prescribed period, and then gently washed off according to the treatment schedule.

Serious risks include severe local dermatitis, secondary skin infection, and rare systemic flu‑like symptoms. Patients should promptly report extensive redness, swelling, fever, or signs of infection to their healthcare provider for evaluation.

Imikeraderm is contraindicated in individuals with known hypersensitivity to imiquimod or any cream components, in patients with compromised immune systems unless advised by a specialist, and should be avoided on mucous membranes, open wounds, or in pregnant women unless the benefit justifies the risk.